Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medexus Pharmaceuticals Inc MEDXF


Primary Symbol: T.MDP

Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. The Company is focused on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy and dermatology. The Company has two divisions: Medexus Pharma Canada and Medexus Pharma USA... see more

TSX:MDP - Post Discussion

Medexus Pharmaceuticals Inc > Revenue numbers
View:
Post by GoldenArm on May 20, 2021 1:24pm

Revenue numbers

First I apologize for not reading my posts before posting. I made a lot of mistakes in spelling, grammer and probably syntax.

Q4 2021 numbers guesses anyone? More than than Q4 2020 $25M and inline with Q3 2021 $31M to $32M or slightly higher at $35M

Next treo coming to Canada possibly in June.

Treosulfan: On February 2, 2021, the Company entered into an exclusive license to commercialize treosulfan in the United States. The Prescription Drug User Fee Act date is scheduled for August 2021 with potential to commercialize shortly thereafter. In accordance with the Orphan Drug Act, seven years of exclusivity for this indication is expected upon FDA approval. The current market leading alkylating agent for Allo-HSCT reached peak sales of US$126M in the U.S. As announced by the Company on September 10, 2020, Health Canada granted priority review for treosulfan, which could be approved as early as June 2021. Medexus is currently negotiating the licence in anticipation of a full commercial launch following Health Canada approval.


We should see revenues from Gleolan as well

Gleolan®: On February 25, 2021, Medexus initiated commercial launch of Gleolan® in Canada, replacing use under the Health Canada Special Access Program.

Not sure what is happening with Triamcinolone Hexacetonide (TH)  They were supposed to get, if I read it correctly, import ok in US from FDA before being able to sell (market) the drug which is in short supply.
Comment by Rockafellow on May 20, 2021 2:09pm
Forecast is $110 mil US only if treosufate is approved by FDA in August ... ... .. Nasdaq listing is belong .... We will c $10 CDN before too long as the cards say ... .. ... Ocean says $14 for sure & she is usual right. ...
Comment by oceaneleven on May 20, 2021 3:02pm
7.10 shares will become free trading in June from the last tea & bake sale...we will have lots of juicy news to help us longs out... The offering consisted of 4,581,689 units at a price of C$7.10 per unit for total gross proceeds of approximately C$32,529,992, including 597,611 units sold pursuant to the exercise in full of the over-allotment option. The offering was led by Raymond James ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities